UNAIDS and the Gates Foundation convened a meeting on 5-6 June, 2025 to consider mathematical modelling evidence on the anticipated epidemiologic impact and cost-efficiency of long-acting injectable lenacapavir (LEN) for HIV prevention in low- and middle-income countries.

Scaling up primary HIV prevention, including pre-exposure prophylaxis (PrEP), is essential to closing the prevention gap and reducing the number of new HIV infections, especially as countries approach the 95–95–95 treatment targets1 but continue to face a stagnant or rising incidence of HIV among people from key and priority populations. Injectable lenacapavir is a new long-acting injectable antiretroviral medicine given every six months for HIV prevention. In clinical trials, lenacapavir was found to be safe and effective, with 96–100% reduction in HIV acquisition compared with background rates.